

**Amendments to the Claims under 37 C.F.R. § 1.121**

Claims 1-26 (cancelled).

Claim 27 (previously presented): An isolated nucleic acid molecule comprising the nucleotide sequence as set forth in SEQ ID NO: 3.

Claims 28-48 (cancelled).

Claim 49 (previously presented): An isolated nucleic acid molecule encoding a polypeptide having the ability to bind TNF, wherein said polypeptide comprises the amino acid sequence as set forth in SEQ ID NO: 4.

Claims 50-63 (cancelled).

Claim 64 (previously presented): The isolated nucleic acid molecule of Claim 49, wherein said polypeptide further comprises an amino-terminal methionine.

Claims 65-66 (cancelled).

Claim 67 (previously presented): An isolated nucleic acid molecule encoding a polypeptide having the ability to bind TNF, wherein said polypeptide consists of the amino acid sequence of SEQ ID NO: 4.

Claim 68 (previously presented): An isolated nucleic acid molecule encoding a polypeptide having the ability to bind TNF, wherein said polypeptide consists of the amino acid sequence of SEQ ID NO: 4 and an amino-terminal methionine.

Claims 69-70 (cancelled).

Claim 71 (previously presented): The nucleic acid molecule of Claim 49, wherein said nucleic acid molecule encodes a polypeptide having at least one additional amino acid at the amino-terminus, at the carboxyl-terminus, or at both the amino-terminus and the carboxyl-terminus.

Claim 72 (previously presented): The nucleic acid of Claim 71, wherein said nucleic acid molecule encodes a polypeptide having at least one additional amino acid at the amino-terminus.

Claim 73 (previously presented): The nucleic acid of Claim 72, wherein said nucleic acid molecule encodes a polypeptide having a methionine at the amino-terminus.

Claim 74 (previously presented): The nucleic acid of Claim 71, wherein said nucleic acid molecule encodes a polypeptide having at least one additional amino acid at the carboxyl-terminus.

Claim 75 (cancelled).

Claim 76 (previously presented): A vector comprising the nucleic acid molecule of any of Claims 27, 49, 64, 67, or 68.

Claim 77 (previously presented): A vector comprising the nucleic acid molecule of Claim 27.

Claim 78 (cancelled).

Claim 79 (previously presented): A vector comprising the nucleic acid molecule of Claim 49.

Claim 80 (cancelled).

Claim 81 (previously presented): A vector comprising the nucleic acid molecule of Claim 64.

Claim 82 (previously presented): A vector comprising the nucleic acid molecule of Claim 68.

Claim 83 (previously presented): The vector of Claim 76, wherein said vector is an expression vector.

Claim 84 (previously presented): The vector of Claim 83, wherein said nucleic acid molecule comprises promoter DNA.

Claim 85 (previously presented): The vector of Claim 76, wherein said vector is replicable in a prokaryotic cell.

Claim 86 (previously presented): The vector of Claim 85, wherein the prokaryotic cell is *Escherichia coli*.

Claims 87-88 (cancelled).

Claim 89 (previously presented): The vector of Claim 76, wherein said vector is replicable in a eukaryotic cell.

Claim 90 (previously presented): The vector of Claim 89, wherein the eukaryotic cell is a mammalian cell.

Claim 91 (previously presented): The vector of Claim 90, wherein the mammalian cell is a Chinese Hamster Ovary cell or a COS cell.

Claims 92-93 (cancelled).

Claim 94 (previously presented): A vector that is replicable in a Chinese Hamster Ovary cell, and wherein said vector comprises the nucleic acid molecule of Claim 67.

Claim 95 (cancelled).

Claim 96 (previously presented): The vector of Claim 89, wherein the eukaryotic cell is a yeast cell.

Claim 97 (currently amended): A cultured recombinant host cell comprising the vector of Claim 76.

Claims 98-101 (cancelled).

Claim 102 (currently amended): A cultured recombinant host cell comprising the vector of Claim 94.

Claim 103 (cancelled).

Claim 104 (currently amended): A cultured recombinant host cell comprising the recombinant nucleic acid molecule of any of Claims 27, 49, 64, 67, or 68.

Claim 105 (currently amended): The cultured recombinant host cell of Claim 104, wherein said recombinant nucleic acid molecule encodes a polypeptide further comprising an amino-terminal methionine.

Claims 106-109 (cancelled).

Claim 110 (currently amended): The cultured recombinant host cell of Claim 104, wherein said recombinant nucleic acid molecule encodes a polypeptide consisting of the amino acid sequence of SEQ ID NO: 4.

Claim 111 (currently amended): The cultured recombinant host cell of Claim 104, wherein said recombinant nucleic acid molecule encodes a polypeptide consisting of the amino acid

sequence of SEQ ID NO: 4 and an amino-terminal methionine.

Claims 112-113 (cancelled).

Claim 114 (currently amended): The cultured recombinant host cell of Claim 97, wherein the cultured recombinant host cell is a prokaryotic cell.

Claim 115 (currently amended): The cultured recombinant host cell of Claim 114, wherein the prokaryotic cell is *Escherichia coli*.

Claims 116-118 (cancelled).

Claim 119 (currently amended): The recombinant host cell process of Claim 111-176, wherein the prokaryotic eukaryotic cell is *Escherichia coli* a yeast cell.

Claim 120 (cancelled).

Claim 121 (currently amended): The cultured recombinant host cell of Claim 97, wherein the cultured recombinant host cell is a eukaryotic cell.

Claim 122 (currently amended): The cultured recombinant host cell of Claim 121, wherein the eukaryotic cell is a mammalian cell.

Claim 123 (currently amended): The cultured recombinant host cell of Claim 122 wherein the mammalian cell is a Chinese Hamster Ovary cell or a COS cell.

Claims 124-125 (cancelled).

Claim 126 (currently amended): The cultured recombinant host cell of Claim 110, wherein the cultured recombinant host cell is a Chinese Hamster Ovary cell.

Claim 127 (cancelled).

Claim 128 (currently amended): The cultured recombinant host cell of Claim 121, wherein the eukaryotic cell is a yeast cell.

Claim 129 (currently amended): The cultured recombinant host cell of Claim 104, wherein the recombinant nucleic acid comprises promoter DNA other than the promoter DNA for SEQ ID NO: 1.

Claim 130 (cancelled).

Claim 131 (currently amended): A process of producing a recombinant polypeptide having the ability to bind TNF comprising culturing the recombinant host cell of Claim 97 under suitable conditions to express the polypeptide.

Claim 132 (currently amended): The process of claim 131, further comprising culturing the recombinant host cell under suitable conditions to amplify the recombinant nucleic acid molecule.

Claim 133 (currently amended): The process of Claim 131, wherein the recombinant host cell is a prokaryotic cell.

Claim 134 (previously presented): The process of Claim 133, wherein the prokaryotic cell is *Escherichia coli*.

Claim 135 (currently amended): The process of Claim 131, wherein the recombinant host cell is a eukaryotic cell.

Claim 136-137 (cancelled).

Claim 138 (previously presented): The process of Claim 135, wherein the eukaryotic cell is a mammalian cell.

Claim 139 (previously presented): The process of Claim 138, wherein the mammalian cell is a Chinese Hamster Ovary cell or a COS cell.

Claims 140-143 (cancelled).

Claim 144 (previously presented): The process of Claim 135, wherein the eukaryotic cell is a yeast cell.

Claim 145 (previously presented): The process of Claim 131, wherein said polypeptide is expressed as a multimer.

Claim 146 (previously presented): The process of Claim 131, further comprising recovering the polypeptide from the culture.

Claim 147 (previously presented): The process of Claim 146, further comprising chemically derivatizing the recovered polypeptide.

Claim 148 (previously presented): The process of Claim 146, wherein said recovered polypeptide is formulated to comprise said polypeptide and a pharmaceutically acceptable carrier.

Claim 149 (currently amended): The cultured recombinant host cell of Claim 104, wherein the cultured recombinant host cell is a prokaryotic cell.

Claim 150 (currently amended): The cultured recombinant host cell of Claim 149, wherein the prokaryotic cell is *Escherichia coli*.

Claim 151 (currently amended): The cultured recombinant host cell of Claim 104, wherein the cultured recombinant host cell is a eukaryotic cell.

Claim 152 (currently amended): The cultured recombinant host cell of Claim 151, wherein the eukaryotic cell is a mammalian cell.

Claim 153 (currently amended): The cultured recombinant host cell of Claim 152 wherein the mammalian cell is a Chinese Hamster Ovary cell or a COS cell.

Claim 154 (currently amended): The cultured recombinant host cell of Claim 151, wherein the eukaryotic cell is a yeast cell.

Claim 155 (currently amended): A process of producing a recombinant polypeptide having the ability to bind TNF comprising culturing the recombinant host cell of Claim 104 under suitable conditions to express the polypeptide.

Claim 156 (currently amended): The process of Claim 155, wherein the recombinant host cell is a prokaryotic cell.

Claim 157 (previously presented): The process of Claim 156, wherein the prokaryotic cell is *Escherichia coli*.

Claim 158 (currently amended): The process of Claim 155, wherein the recombinant host cell is a eukaryotic cell.

Claim 159 (previously presented): The process of Claim 158, wherein the eukaryotic cell is a mammalian cell.

Claim 160 (previously presented): The process of Claim 159, wherein the mammalian cell is a Chinese Hamster Ovary cell or a COS cell.

Claim 161 (previously presented): The process of Claim 158, wherein the eukaryotic cell is a yeast cell.

Claim 162 (previously presented): The process of Claim 155, wherein said polypeptide is expressed as a multimer.

Claim 163 (previously presented): The process of Claim 155, further comprising recovering the polypeptide from the culture.

Claim 164 (previously presented): The process of Claim 163, further comprising chemically derivatizing the recovered polypeptide.

Claim 165 (previously presented): The process of Claim 164, wherein said recovered polypeptide is formulated to comprise said polypeptide and a pharmaceutically acceptable carrier.

Claim 166 (previously presented): The process of Claim 163, wherein said recovered polypeptide is formulated to comprise said polypeptide and a pharmaceutically acceptable carrier.

Claim 167 (currently amended): The process of claim 155, further comprising culturing the ~~recombinant~~-host cell under suitable conditions to amplify the recombinant nucleic acid molecule.

Claim 168 (currently amended): A process of producing a recombinant polypeptide having the ability to bind TNF comprising culturing a ~~recombinant~~-host cell comprising a nucleic acid molecule that encodes a polypeptide consisting of the amino acid sequence of SEQ ID NO: 4 and an amino-terminal methionine under suitable conditions to express the polypeptide.

Claim 169 (cancelled).

Claim 170 (currently amended): A process of producing a recombinant polypeptide having the ability to bind TNF comprising culturing a ~~recombinant~~-host cell comprising a nucleic acid molecule that encodes a polypeptide comprising the amino acid sequence of SEQ ID NO: 4 under suitable conditions to express the polypeptide.

Claim 171 (cancelled).

Claim 172 (currently amended): A process of producing a recombinant polypeptide having the ability to bind TNF comprising culturing a ~~recombinant~~-host cell comprising a nucleic acid molecule that encodes a polypeptide consisting of the amino acid sequence of SEQ ID NO: 4 under suitable conditions to express the polypeptide.

Claim 173 (cancelled).

Claim 174 (currently amended): The process of any of Claims 168, 170, or 172, wherein the ~~recombinant~~-host cell is a prokaryotic cell.

Claim 175 (previously presented): The process of Claim 174, wherein the prokaryotic cell is *Escherichia coli*.

Claim 176 (currently amended): The process of any of Claims 168, 170, or 172, wherein the ~~recombinant~~-host cell is a eukaryotic cell.

Claim 177 (previously presented): The process of Claim 176, wherein the eukaryotic cell is a Chinese Hamster Ovary cell.

Claim 178 (previously presented): The process of Claim 147, wherein said recovered polypeptide is formulated to comprise said polypeptide and a pharmaceutically acceptable carrier.